YONKERS, N.Y., May 11, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including ...
On May 11, 2020, ContraFect Corp. (NASDAQ:CFRX) announced four abstracts were published in the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) abstract book. Both the ...
Oral ibrexafungerp continues to show potential to address a broad range of indications ranging from vaginal yeast infections to life-threatening refractory invasive fungal infections Findings indicate ...
CHELMSFORD, Mass., May 21, 2020 /PRNewswire/ -- First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, ...
VANCOUVER, April 3, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that seven abstracts ...
The European Society of Clinical Microbiology and Infectious Disease (ESCMID) – an organization that explores risks, knowledge sharing and best practices in the fight against infectious disease – has ...
Oral ibrexafungerp continues to show potential to address a broad range of indications ranging from vaginal yeast infections to life-threatening refractory invasive fungal infections Findings indicate ...
On May 11, 2020, ContraFect Corp. (NASDAQ:CFRX) announced four abstracts were published in the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) abstract book. Both the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback